These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9051872

  • 1. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
    Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J.
    Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
    [Abstract] [Full Text] [Related]

  • 2. Gastroduodenal tolerability of highly specific cyclo-oxygenase-2 inhibitor.
    Hayllar J, Bjarnason I.
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():30-2. PubMed ID: 9032580
    [Abstract] [Full Text] [Related]

  • 3. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [Abstract] [Full Text] [Related]

  • 4. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [Abstract] [Full Text] [Related]

  • 5. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS.
    JAMA; 1999 Nov 24; 282(20):1921-8. PubMed ID: 10580457
    [Abstract] [Full Text] [Related]

  • 6. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat.
    Blume C, Heise G, Mühlfeld A, Bach D, Schrör K, Gerhardz CD, Grabensee B, Heering P.
    Kidney Int; 1999 Nov 24; 56(5):1770-8. PubMed ID: 10571785
    [Abstract] [Full Text] [Related]

  • 7. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS.
    Mayo Clin Proc; 1999 Nov 24; 74(11):1095-105. PubMed ID: 10560596
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
    Lohmander LS, McKeith D, Svensson O, Malmenäs M, Bolin L, Kalla A, Genti G, Szechinski J, Ramos-Remus C, STAR Multinational Study Group.
    Ann Rheum Dis; 2005 Mar 24; 64(3):449-56. PubMed ID: 15345500
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
    Harris SI, Kuss M, Hubbard RC, Goldstein JL.
    Clin Ther; 2001 Sep 24; 23(9):1422-8. PubMed ID: 11589257
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL, Aisenberg J, Lanza F, Schwartz H, Sands GH, Berger MF, Pan S.
    Clin Ther; 2006 Mar 24; 28(3):340-51. PubMed ID: 16750449
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS.
    Scand J Rheumatol Suppl; 1999 Mar 24; 109():31-7. PubMed ID: 10422544
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.
    Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, Gudjonsson H, Oddsson E, Price AB, Fitzgerald DJ, Bjarnason I.
    Gut; 2001 Mar 24; 48(3):339-46. PubMed ID: 11171823
    [Abstract] [Full Text] [Related]

  • 19. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct 24; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.